Aggressive blood cancers: Response of multiple myeloma patients to Carfilzomib after other treatments have failed

A new proteasome inhibitor may hold hope for patients with multiple myeloma who have been treated unsuccessfully with other drugs. The medication has already demonstrated antitumor activity in phase 1 and 2 studies in patients with relapsed or refractory myeloma.

Read the whole article on Science Daily

More from Science Daily